This article was written by 43.8K Followers Michael Kramer is the founder of Mott Capital, and is a long-only investor who focuses on macro
Investing News
This Magnificent S&P 500 Dividend Stock Is Down 18% — Time to Buy?
It’s been an unusually bad year for this drugmaker, but it’s essential to look beyond that. Vertex Pharmaceuticals (VRTX -0.45%) is usually a market-beater,
Huge News for AST SpaceMobile Stock Investors
Brett Schafer, The Motley Fool August 24, 2025 at 9:00 AM Key Points AST SpaceMobile is about to bring satellite internet directly to smartphones.
Plug Power Stock Is Cheap, but Does That Make It a Buy Now?
Leo Sun, The Motley Fool August 24, 2025 at 10:10 AM Key Points Plug Power trades about 99% below its IPO price. It reinvented
The fragmented future of global trade
Over the past four to five months, the global economy has undergone massive changes, creating uncertainty in international trade, intensifying trade conflicts, and triggering
The Tiny Country With the Fastest-Growing Economy in the World Exceeds Forecast
A view of the central business area in Mahdia Town, Guyana. Credit: Luisdavidleonlopez , CC BY-SA 4.0/Wikipedia The tiny country that boasts the fastest-growing
Japanese neurologist makes viral statement on daily exercise: “Every drop of sweat counts for brain health”
A growing body of research confirms what many have long suspected: regular physical activity benefits not just the body, but also the brain. Recently,
This Analyst Thinks NVIDIA Will Fall 40%
Douglas A. McIntyre August 24, 2025 at 11:01 AM Seaport Global Securities analyst Jay Goldberg downgraded NVIDIA (NASDAQ: NVDA) three months ago. He put
If You'd Invested $5,000 in Nvidia Stock 3 Years Ago, Here's How Much You'd Have Today
The rise of artificial intelligence has led to truly remarkable gains for the company. The advent of generative artificial intelligence (AI) has driven impressive
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
Time is running out for the company to mount a comeback. There’s at least one good thing to say about Iovance Biotherapeutics (IOVA 5.91%),